Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
depigoid birch
- Development stage
- Phase 3
- Lead developer
- Leti Pharma
- Modality
- Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
Depigoid Birch is a subcutaneous immunotherapy product consisting of a modified (depigmented and glutaraldehyde-polymerized) allergenic extract from Betula alba (birch) pollen. It is designed for the treatment of IgE-mediated allergic diseases such as allergic rhinitis and rhinoconjunctivitis caused by sensitization to birch pollen. The modification process reduces the risk of severe allergic reactions while maintaining immunogenicity. Its mechanism involves immunomodulation—specifically inducing immune tolerance to the relevant allergens through repeated controlled exposure, leading to changes in specific IgE and IgG antibody profiles and modulation of T-cell responses[1][2][6]. Developed by LETI Pharma GmbH (a subsidiary of Laboratorios LETI SL), it has been evaluated in multiple randomized controlled trials for efficacy and safety in both adults and adolescents with seasonal allergic rhinitis/rhinoconjunctivitis[1][2][6].
- Brand names
- Depigoid BirchDepigoid Birch 5000
- Other names
- depigmented glutaraldehyde polymerized birch pollen allergenic extractDepigoid Birch 10000
02
Targets
MHC II (Major histocompatibility complex class II receptor)IgE (Immunoglobulin E)
Beyond the preview
Go deeper on depigoid birch.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on depigoid birch.